Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection?
Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection?
复制标题
甲硝唑治疗艰难梭菌感染的有效性下降？
DOI：
10.1086/588294
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
M. Wilcox
中科院分区：
文献类型：
--
作者：
E. Kuijper;M. Wilcox
自从出现了一种新的艰难梭菌强毒株，其特征为毒素型III、北美PFGE 1型（NAP 1）、限制性内切核酸酶分析组BI型和PCR核糖体型027（027型），在北美和欧洲报告了多次暴发[1，2]。第一批报告来自加拿大，其中魁北克省是最早和最严重的影响[3]。在美国，至少有38个州受到新出现的菌株的影响[4]。在英国和荷兰爆发之后，该菌株在整个欧洲迅速传播，目前包括18个国家[5]。一个令人担忧的新进展是欧洲的暴发，可归因于携带ermB基因的克林霉素耐药NAP 1/027菌株（MIC，>256 mg/L）[6]。克林霉素一直被认为是一种“保护性”抗生素的发展，C。艰难梭菌相关疾病（CDAD）可归因于NAP 1/027，但对这种药物的耐药性增加了C.在-
Since the emergence of a new virulent strain of Clostridium difficile characterized as toxinotype III, North American PFGE type 1 (NAP1), restriction endonuclease analysis group type BI, and PCR ribotype 027 (type 027) multiple outbreaks have been reported in North America and Europe [1, 2]. The first reports were from Canada, where the province of Quebec was the earliest and most severely affected [3]. In the United States, at least 38 states have been affected by the new emerging strain [4]. Outbreaks in the United Kingdom and The Netherlands have been followed by a rapid spread of the strain throughout Europe, now including 18 countries [5]. A worrisome new development is outbreaks in Europe attributable to clindamycin-resistant NAP1/027 strains (MIC, >256 mg/L) that harbor the ermB gene [6]. Clindamycin has been considered to be a "protective" antibiotic for the development of C. difficile-associated disease (CDAD) attributable to NAP1/027, but resistance to this agent increases the risk of C. difficile in-